Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$39.99 +0.7%	$27.01	$16.50 ▼ $40.39	$3.46B	N/A	13,859 shs	19,479 shs
CRMD CorMedix	$14.97 -4.8%	$11.96	$3.61 ▼ $17.43	$1.07B	1.62	1.27 million shs	1.43 million shs
NAMS NewAmsterdam Pharma	$18.33 -0.4%	$18.64	$14.06 ▼ $27.29	$2.07B	-0.03	705,990 shs	946,313 shs
OGN Organon & Co.	$10.00 +0.5%	$9.82	$8.01 ▼ $23.10	$2.59B	0.58	3.48 million shs	2.81 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+0.73%	+11.45%	+51.02%	+97.97%	+3,998,999,900.00%
CRMD CorMedix	-4.77%	+10.24%	+21.12%	+123.10%	+258.13%
NAMS NewAmsterdam Pharma	-0.38%	+0.71%	+4.09%	-18.21%	-6.81%
OGN Organon & Co.	+0.56%	+1.15%	+15.07%	-31.34%	-51.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	0.9929 of 5 stars	2.6	1.0	0.0	0.0	2.0	0.0	0.6
NAMS NewAmsterdam Pharma	3.0786 of 5 stars	3.5	2.0	0.0	0.0	2.5	5.0	0.0
OGN Organon & Co.	4.709 of 5 stars	3.3	2.0	1.7	3.7	1.7	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
CRMD CorMedix	3.17	Buy	$16.67	11.33% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	133.98% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	80.00% Upside

Current Analyst Ratings Breakdown

Latest CRMD, OGN, NAMS, and AAPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
6/23/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
6/20/2025	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$13.00 ➝ $17.00
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/7/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $15.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	25.93	N/A	N/A	$0.48 per share	83.31
CRMD CorMedix	$43.47M	23.36	N/A	N/A	$1.40 per share	10.69
NAMS NewAmsterdam Pharma	$45.56M	45.17	N/A	N/A	$8.20 per share	2.24
OGN Organon & Co.	$6.40B	0.41	$4.95 per share	2.02	$1.83 per share	5.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	-$17.93M	$0.22	68.05	15.93	N/A	20.81%	22.57%	17.02%	8/13/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.47	2.67	1.04	11.92%	227.43%	7.34%	8/5/2025 (Estimated)

Latest CRMD, OGN, NAMS, and AAPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/6/2025	Q1 2025	CRMD CorMedix	$0.25	$0.30	+$0.05	$0.30	$38.90 million	$39.08 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.80%	N/A	2.78%	N/A

Latest CRMD, OGN, NAMS, and AAPG Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
CRMD CorMedix	N/A	4.21	3.99
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
OGN Organon & Co.	16.49	1.67	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
CRMD CorMedix	34.18%
NAMS NewAmsterdam Pharma	89.89%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
CRMD CorMedix	5.30%
NAMS NewAmsterdam Pharma	20.84%
OGN Organon & Co.	1.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
CRMD CorMedix	30	67.82 million	64.23 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable

CRMD, OGN, NAMS, and AAPG Headlines

Recent News About These Companies

OGN - Organon & Co Ordinary Shares Valuation - Morningstar

4 hours ago | morningstar.comM

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN - Morningstar

4 hours ago | morningstar.comM

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

4 hours ago | investing.com

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

5 hours ago | globenewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

June 25 at 6:15 PM | globenewswire.com

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

June 25 at 10:00 AM | zacks.com

Organon & Co. (OGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

June 25 at 9:00 AM | prnewswire.com

ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 24 at 11:08 PM | globenewswire.com

Investors who lost money on Organon & Co.(OGN) should contact Levi & Korsinsky about pending Class Action - OGN

June 24 at 4:16 PM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

June 24 at 11:32 AM | globenewswire.com

Organon & Co. (OGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

June 24 at 11:00 AM | prnewswire.com

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

June 24 at 10:44 AM | prnewswire.com

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm

June 24 at 10:42 AM | prnewswire.com

Organon & Co. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN

June 24 at 9:00 AM | prnewswire.com

OGN STOCK LOSS: Organon & Co. Shareholders are Alerted of Imminent July 22 Class Action Deadline -- Contact BFA Law (NYSE:OGN)

June 24 at 8:18 AM | globenewswire.com

Organon & Co. (NYSE:OGN) Shares Purchased by Janney Montgomery Scott LLC

June 24 at 3:34 AM | marketbeat.com

Organon & Co. (NYSE:OGN) Receives Average Recommendation of "Moderate Buy" from Analysts

June 24 at 2:11 AM | americanbankingnews.com

OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)

June 23 at 10:51 PM | morningstar.comM

OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)

June 23 at 10:51 PM | morningstar.comM

Contact The Gross Law Firm by July 22, 2025 Deadline to Join Class Action Against Organon & Co. (OGN)

June 23 at 4:00 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN

June 23 at 11:06 AM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD, OGN, NAMS, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$39.99 +0.29 (+0.73%)

As of 06/25/2025 04:00 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

CorMedix NASDAQ:CRMD

$14.97 -0.75 (-4.77%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$15.06 +0.09 (+0.63%)

As of 06/25/2025 07:59 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

NewAmsterdam Pharma NASDAQ:NAMS

$18.33 -0.07 (-0.38%)

Closing price 06/25/2025 04:00 PM Eastern

Extended Trading

$17.90 -0.43 (-2.37%)

As of 06/25/2025 06:13 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Organon & Co. NYSE:OGN

$10.00 +0.05 (+0.50%)

Closing price 06/25/2025 03:59 PM Eastern

Extended Trading

$9.97 -0.03 (-0.34%)

As of 06/25/2025 07:55 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time